Brain Advance Access published online on August 4, 2005
Brain, doi:10.1093/brain/awh607
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Pacific Parkinson's Research Centre, University of British Columbia
* To whom correspondence should be addressed. Parkinson's disease may arise from multiple aetiologies, including genetic mutations that are for the most part uncommon. We describe here the positron emission tomography (PET) findings in clinically affected and asymptomatic, high-risk members of two autosomal dominantly inherited Parkinson's disease kindreds with recently described mutations at the PARK8 locus, in a novel gene encoding a leucine-rich repeat kinase (LRRK2). Affected family members have L-dopa-responsive parkinsonism with loss of dopaminergic nigral neurons and pleomorphic subcellular pathology. Fifteen family members underwent PET using: 18F-6-fluoro-L-dopa (18F-dopa) to assess dopamine (DA) synthesis and storage, 11C-(±)
Received February 10, 2005
Revised May 30, 2005
Accepted July 4, 2005
Article
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation
2 Mayo Clinic, Jacksonville, FL, USA
3 Department of Physics and Astronomy, University of British Columbia
4 TRIUMF, Vancouver, BC, Canada
5 Department of Neurodegenerative disorders, Hertie Institute for Clinical Brain Research, Center of Neurology, University of Tubingen, Tubingen, Germany
A. Jon Stoessl, E-mail: jstoessl{at}interchange.ubc.ca
![]()
Abstract
-dihydrotetrabenazine (11C-DTBZ) for the vesicular monoamine transporter, and 11C-d-threo-methylphenidate (11C-MP) for the membrane dopamine transporter (DAT). Measurements were compared with normal (n = 33) and sporadic Parkinson's disease (sPD) (n = 67) control groups. Four clinically affected members had findings similar to sPD, with impaired presynaptic DA function affecting the putamen more than the caudate. In two affected members, D2 dopamine receptor binding was intact. Two asymptomatic mutation carriers had abnormal DAT binding with another two developing such abnormalities over 4 years of follow-up. In these individuals, 18F-dopa uptake remained normal, although two of them also displayed abnormal 11C-DTBZ binding. Our study demonstrates that the in vivo neurochemical phenotype of LRRK2 mutations is indistinguishable from that of sPD, despite the pathological heterogeneity of the condition. Furthermore, we suggest that compensatory changes including downregulation of the DAT and upregulation of decarboxylase activity may delay the onset of parkinsonian symptoms.
*These authors contributed equally to this work
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. R. Troiano, R. de la Fuente-Fernandez, V. Sossi, M. Schulzer, E. Mak, T. J. Ruth, and A. J. Stoessl PET demonstrates reduced dopamine transporter expression in PD with dyskinesias Neurology, April 7, 2009; 72(14): 1211 - 1216. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Marek and D. Jennings Can we image premotor Parkinson disease? Neurology, February 17, 2009; 72(7_Supplement_2): S21 - S26. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nandhagopal, E. Mak, M. Schulzer, J. McKenzie, S. McCormick, V. Sossi, T. J. Ruth, A. Strongosky, M. J. Farrer, Z. K. Wszolek, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study Neurology, November 25, 2008; 71(22): 1790 - 1795. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nandhagopal, M. J. McKeown, and A. J. Stoessl Invited Article: Functional imaging in Parkinson disease Neurology, April 15, 2008; 70(16_Part_2): 1478 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. -B. Ahn, S. Y. Kim, J. Y. Kim, S. -S. Park, D. S. Lee, H. J.. Min, Y. K. Kim, S. E. Kim, J. -M. Kim, H. -J. Kim, et al. {alpha}-Synuclein gene duplication is present in sporadic Parkinson disease Neurology, January 1, 2008; 70(1): 43 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Klein and M. G. Schlossmacher Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder Neurology, November 27, 2007; 69(22): 2093 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Nichols, V. E. Elsaesser, N. Pankratz, M. W. Pauciulo, D. K. Marek, C. A. Halter, A. Rudolph, C. W. Shults, T. Foroud, and For the Parkinson Study Group PROGENI Investigato LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 Neurology, October 30, 2007; 69(18): 1737 - 1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kas, P. Payoux, M.-O. Habert, Z. Malek, Y. Cointepas, G. El Fakhri, P. Chaumet-Riffaud, E. Itti, and P. Remy Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 123I-FP-CIT Images J. Nucl. Med., September 1, 2007; 48(9): 1459 - 1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Binkofski, K. Reetz, C. Gaser, R. Hilker, J. Hagenah, K. Hedrich, T. van Eimeren, A. Thiel, C. Buchel, P. P. Pramstaller, et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia Neurology, August 28, 2007; 69(9): 842 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Iaccarino, C. Crosio, C. Vitale, G. Sanna, M. T. Carri, and P. Barone Apoptotic mechanisms in mutant LRRK2-mediated cell death Hum. Mol. Genet., June 1, 2007; 16(11): 1319 - 1326. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. V. Schapira The Importance of LRRK2 Mutations in Parkinson Disease. Arch Neurol, September 1, 2006; 63(9): 1225 - 1228. [Full Text] [PDF] |
||||
![]() |
A. H.V. Schapira Etiology of Parkinson's disease Neurology, May 23, 2006; 66(10_suppl_4): S10 - S23. [Abstract] [Full Text] |
||||
![]() |
A. Brice Genetics of Parkinson's disease: LRRK2 on the rise Brain, December 1, 2005; 128(12): 2760 - 2762. [Full Text] [PDF] |
||||
![]() |
N. L. Khan, S. Jain, J. M. Lynch, N. Pavese, P. Abou-Sleiman, J. L. Holton, D. G. Healy, W. P. Gilks, M. G. Sweeney, M. Ganguly, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data Brain, December 1, 2005; 128(12): 2786 - 2796. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. West, D. J. Moore, S. Biskup, A. Bugayenko, W. W. Smith, C. A. Ross, V. L. Dawson, and T. M. Dawson From The Cover: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity PNAS, November 15, 2005; 102(46): 16842 - 16847. [Abstract] [Full Text] [PDF] |
||||





